Skip to main content

Table 1 Event probabilities, cost, hazard ratio, and utility used in the model

From: Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients

Name

Value

Parameter description

SE

Ref

drC

0.03

Discounting rate for costs

 

WHO 2015

drO

0.03

Discounting rate for outcomes

 

WHO 2015

Transitional probabilities

tpRA_RA

0.952

Transition probability from Resolved ACS to Stay Resolved ACS

0.095

 

tpRA_MI

0.012

Transition probability from RA to MI

0.001

Taylor et al. [19]

tpRA_CAr

0.001

Transition probability from RA to Cardiac Arrest

0.001

Taylor et al. [19]

tpRA_Rv

0.035

Transition probability from RA to Revascularization

0.001

Taylor et al. [19]

tpMI_MI

0.049

Transition probability from MI to MI

0.010

Taylor et al. [19]

tpMI_Rv

0.027

Transition probability from MI to Revascularization

0.004

Taylor et al. [19]

tpMI_D_30to34

0.007

Transition probability from MI to Death age 30–34

0.001

Taylor et al. [19]

tpMI_D_35to39

0.009

Transition probability from MI to Death age 35–39

0.001

Taylor et al. [19]

tpMI_D_40to44

0.014

Transition probability from MI to Death age 40–44

0.001

Taylor et al. [19]

tpMI_D_45to49

0.020

Transition probability from MI to Death age 45–49

0.002

Taylor et al. [19]

tpMI_D_50to54

0.032

Transition probability from MI to Death age 50–54

0.003

Taylor et al. [19]

tpMI_D_55to59

0.050

Transition probability from MI to Death age 55–59

0.005

Taylor et al. [19]

tpMI_D_60to64

0.084

Transition probability from MI to Death age 60–64

0.008

Taylor et al. [19]

tpMI_D_65to69

0.131

Transition probability from MI to Death age 65–69

0.013

Taylor et al. [19]

tpMI_D_70to74

0.205

Transition probability from MI to Death age 70–74

0.021

Taylor et al. [19]

tpMI_D_75to79

0.326

Transition probability from MI to Death age 75–79

0.033

Taylor et al. [19]

tpMI_D_80to84

0.508

Transition probability from MI to Death age 80–84

0.051

Taylor et al. [19]

tpCAr_D_30to34

0.004

Transition probability from Cardiac Arrest to Death age 30–34

0.000

Taylor et al. [19]

tpCAr_D_35to39

0.005

Transition probability from Cardiac to Death age 35–39

0.001

Taylor et al. [19]

tpCAr_D_40to44

0.008

Transition probability from Cardiac Arrest to Death age 40–44

0.001

Taylor et al. [19]

tpCAr_D_45to49

0.012

Transition probability from Cardiac Arrest to Death age 45–49

0.001

Taylor et al. [19]

tpCAr_D_50to54

0.018

Transition probability from Cardiac Arrest to Death age 50–54

0.002

Taylor et al. [19]

tpCAr_D_55to59

0.028

Transition probability from Cardiac Arrest to Death age 55–59

0.003

Taylor et al. [19]

tpCAr_D_60to64

0.048

Transition probability from Cardiac Arrest to Death age 60–64

0.005

Taylor et al. [19]

tpCAr_D_65to69

0.074

Transition probability from Cardiac Arrest to Death age 65–69

0.007

Taylor et al. [19]

tpCAr_D_70to74

0.116

Transition probability from Cardiac Arrest to Death age 70–74

0.012

Taylor et al. [19]

tpCAr_D_75to79

0.185

Transition probability from Cardiac Arrest to Death age 75–79

0.019

Taylor et al. [19]

tpCAr_D_80to84

0.288

Transition probability from Cardiac Arrest to Death age 80–84

0.029

Taylor et al. [19]

tpRv_Rv

0.135

Transition probability from Revascularization to Revascularization

0.009

Taylor et al. [19]

tpRv_MI

0.396

Transition probability from Revascularization to MI

0.024

Taylor et al. [19]

tpRv_D_30to34

0.004

Transition probability from Revascularization to Death age 30–34

0.000

Taylor et al. [19]

tpRv_D_35to39

0.005

Transition probability from Revascularization to Death age 35–39

0.001

Taylor et al. [19]

tpRv_D_40to44

0.007

Transition probability from Revascularization to Death age 40–44

0.001

Taylor et al. [19]

tpRv_D_45to49

0.011

Transition probability from Revascularization to Death age 45–49

0.001

Taylor et al. [19]

tpRv_D_50to54

0.017

Transition probability from Revascularization to Death age 50–54

0.002

Taylor et al. [19]

tpRv_D_55to59

0.027

Transition probability from Revascularization to Death age 55–59

0.003

Taylor et al. [19]

tpRv_D_60to64

0.045

Transition probability from Revascularization to Death age 60–64

0.005

Taylor et al. [19]

tpRv_D_65to69

0.071

Transition probability from Revascularization to Death age 65–69

0.007

Taylor et al. [19]

tpRv_D_70to74

0.111

Transition probability from Revascularization to Death age 70–74

0.011

Taylor et al. [19]

tpRv_D_75to79

0.176

Transition probability from Revascularization to Death age 75–79

0.018

Taylor et al. [19]

tpRv_D_80to84

0.274

Transition probability from Revascularization to Death age 80–84

0.027

Taylor et al. [19]

Cost parameters

Direct Costs per Health State

dmcRA

Rp 19,728,100

Direct medical costs associated with Resolved ACS

Rp 197,281

INA-CBGs 2016

dmcMI

Rp 12,118,800

Direct medical costs associated with Myocardial Infarction

Rp 121,188

INA-CBGs 2016

dmcCAr

Rp 7,041,400

Direct medical costs associated with Cardiac Arrest

Rp 70,414

INA-CBGs 2016

dmcRv

Rp 40,024,100

Direct medical costs associated with Revascularization

Rp 400,241

INA-CBGs 2016

Cost of Interventions

cHIS

Rp 3,908,568.00

Direct Medical Cost of using High-Intensity Statin per year

Rp 390,856.80

Indonesia Secondary Hospital Type B

cNHIS

Rp 1,474,656.00

Direct Medical Cost of using Moderate Statin per year

Rp 147,465.60

Indonesia Secondary Hospital Type B

High-Intensity Statin Efficacy

HR_HIS_MI

0.77

HR for MI events by using HIS

0.07

Taylor et al. [19]

HR_HIS_CAr

1.07

HR for Cardiac Arrest events by using HIS

0.11

Taylor et al. [19]

HR_HIS_Rv

0.73

HR for Revascularization events by using HIS

0.04

Taylor et al. [19]

Utility parameters

uRA

0.78

Quality of life for Resolved ACS

0.078

Lin et al. [20]

uMI

0.65

Quality of life for Myocardial Infarction

0.065

Lin et al. [20]

uCAr

0.68

Quality of life for Cardiac Arrest

0.068

Lin et al. [20]

uRv

0.78

Quality of life for Revascularization

0.078

Taylor et al. [19]

  1. Values indicate a numerical reference for each parameter that were derived from previous study to be apply in the current study model
  2. SE (standard error) signifies the lack of certainty in the predicted effect size from each chosen reference